Faes Farma (XMAD:FAE) EBIT : €65.7 Mil (TTM As of Mar. 2024)

View and export this data going back to 2015. Start your Free Trial

What is Faes Farma EBIT?

Faes Farma's earnings before interest and taxes (EBIT) for the three months ended in Mar. 2024 was €35.9 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Mar. 2024 was €65.7 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Faes Farma's annualized ROC % for the quarter that ended in Mar. 2024 was 17.84%. Faes Farma's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2024 was 32.14%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Faes Farma's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2024 was 5.83%.

Faes Farma EBIT Historical Data

The historical data trend for Faes Farma's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Faes Farma EBIT Chart

Faes Farma Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EBIT

Get a 7-Day Free Trial

74.23

85.15

93.18

101.68

103.24

Faes Farma Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Dec23	Mar24
EBIT	Get a 7-Day Free Trial															15.44	32.55	29.83	-	35.92

Competitive Comparison of Faes Farma's EBIT

For the Drug Manufacturers - Specialty & Generic subindustry, Faes Farma's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Faes Farma's EV-to-EBIT Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Faes Farma's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Faes Farma's EV-to-EBIT falls into.

Faes Farma EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €65.7 Mil.

Faes Farma (XMAD:FAE) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Faes Farma's annualized ROC % for the quarter that ended in Mar. 2024 is calculated as:

	ROC % (Q: Mar. 2024 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (Q: Dec. 2023 )	+	Invested Capital (Q: Mar. 2024 ))	/ count )
=	143.672 * ( 1 - 15.54% )	/	( (680.306	+	0)	/ 1 )
=	121.3453712	/	680.306
=	17.84 %

where

	Invested Capital		(Q: Dec. 2023 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	776.029	-	47.972	-	( 47.751	-	max(0, 86.818	-	290.286	+	47.751	))
=	680.306

	Invested Capital		(Q: Mar. 2024 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	0	-	0	-	( 0	-	max(0, 0	-	0	+	0	))
=	0

Note: The Operating Income data used here is four times the quarterly (Mar. 2024) data.

2. Joel Greenblatt's definition of Return on Capital:

Faes Farma's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2024 is calculated as:

	ROC (Joel Greenblatt) %		(Q: Mar. 2024 )
=	EBIT	/	Average of (Net fixed Assets	+	Net Working Capital)
=	EBIT	/	Average of (Property, Plant and Equipment	+	Net Working Capital)
			Q: Dec. 2023		Q: Mar. 2024
=	EBIT	/	( ( (Property, Plant and Equipment + Net Working Capital)	+	(Property, Plant and Equipment + Net Working Capital) )	/	count )
=	143.672	/	( ( (280.615 + max(166.399, 0))	+	(0 + max(0, 0)) )	/	1 )
=	143.672	/	( ( 447.014	+	0 )	/	1 )
=	143.672	/	447.014
=	32.14 %

where Working Capital is:

	Working Capital		(Q: Dec. 2023 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(104.092	+	128.656	+	0.94600000000003)	-	(47.972	+	0	+	19.323)
=	166.399

	Working Capital		(Q: Mar. 2024 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0	+	0	+	0)	-	(0	+	0	+	0)
=	0

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Mar. 2024) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Faes Farma's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %	=	EBIT (TTM)	/	Enterprise Value (Q: Mar. 2024 )
	=	65.745	/	1127.765
	=	5.83 %

Faes Farma EBIT Related Terms

Thank you for viewing the detailed overview of Faes Farma's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Faes Farma (XMAD:FAE) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Faes Farma SA (XMAD:FAE) » Definitions » EBIT

Comparable Companies

Traded in Other Exchanges

0K9H:UK FFEA:Germany

Address

Maximo Aguirre, 14, Leioa, Vizcaya, ESP, 48940

Website

http://www.faes.es

Faes Farma SA is a pharmaceutical company that specializes in the research, production, distribution, and sale of prescription and generic drugs, over-the-counter medicines, food supplements and personal care treatments, as well as raw materials for the pharmaceutical use. The company develops new drugs for the treatment of allergy, venous insufficiency, and irritable bowel syndrome. It also provides animal nutrition products. Faes Farma exports its products to more than 60 countries and has operations in Spain, Portugal, Chile, and Mexico, among others.

Faes Farma (XMAD:FAE) Headlines

No Headlines